Table 2.
Patient Characteristics at the Time of CMR (n = 290)
| Age, years (SD) | 53.1 (12.2) |
| Women, n (%) | 141 (48.6) |
| Race | |
| Caucasian, n (%) | 233 (80.3) |
| African-American, n (%) | 50 (17.2) |
| Other, n (%) | 7 (2.4) |
| Extra-cardiac sarcoidosis Involvement (may be more than one) | |
| Lung, n (%) | 260 (89.7) |
| Skin, n (%) | 27 (9.3) |
| Liver, n (%) | 23 (7.9) |
| Eye, n (%) | 19 (6.6) |
| Nervous system, n (%) | 11 (3.8) |
| Other, n (%) | 96 (33.6) |
| Cardiac symptoms | |
| Palpitations, n (%) | 97 (33.4) |
| Chest pain, n (%) | 100 (34.5) |
| Syncope, n (%) | 14 (4.8) |
| NYHA functional class (I/II/III/IV), n (%) | 92/43/22/13 (31.7/14.8/7.6/4.5) |
| Comorbidities | |
| Hypertension, n (%) | 153 (52.8) |
| Dyslipidemia, n (%) | 136 (46.9) |
| Diabetes mellitus, n (%) | 69 (23.8) |
| Former tobacco use, n (%) | 120 (41.4) |
| Tobacco use, n (%) | 28 (9.7) |
| Coronary artery disease, n (%) | 31 (10.7) |
| Pulmonary hypertension, n (%) | 48 (16.6) |
| Medications | |
| Aspirin, n (%) | 90 (31.0) |
| Beta-blockers, n (%) | 87 (30.0) |
| ACE-inhibitor/ Angiotensin receptor blocker, n (%) | 87 (30.0) |
| Statin, n (%) | 91 (31.4) |
| Steroids, n (%) | 98 (33.8) |
| Non-steroidal immune modulatory agents, n (%) | 56 (19.3) |
| Arrhythmia prior to CMR | |
| PVCs, n (%) | 70 (24.1) |
| Ventricular arrhythmia (sustained or non-sustained), n (%) | 20 (6.9) |
| Sustained VT | 7 (2.4) |
| Aborted cardiac arrest | 1 (0.3) |
| Supraventricular tachycardia, n (%) | 27 (9.3) |
| Atrial fibrillation/Flutter, n (%) | 33 (11.3) |
| Advanced AVB (2nd degree Type 2 or 3rd degree), n (%) | 14 (4.8) |
| CMR findings | |
| LVEDVI, ml/m2 (IQR) | 59.9 (50.3 – 71.9) |
| LVESVI, ml/m2 (IQR) | 26.3 (20.8 – 32.5) |
| LVEF, % (IQR) | 56.6 (53.0 – 60.3) |
| LVEF ≤35%, n (%) | 20 (6.9) |
| RVEDVI, ml/m2 (IQR) | 62.7 (53.3 – 72.8) |
| RVESVI, ml/m2 (IQR) | 28.9 (23.7 – 36.8) |
| RVEF, % (IQR) | 52.5 (49.1 – 56.9) |
| LV LGE, n (%) | 87 (30.0) |
Values are n (%), mean ± SD or median (interquartile range).
ACE = angiotensin converting enzyme, AVB = atrioventricular block; CMR = cardiovascular magnetic resonance; EDVI = end-diastolic volume index; EF = ejection fraction; ESVI = end-systolic volume index; LV = left ventricle; LGE = late gadolinium enhancement; NYHA = New York Heart Association; PVC = premature ventricular complexes; RV = right ventricle; VT = ventricular tachycardia